PureTech Health (LON:PRTC) Stock Price Up 9.8% – Still a Buy?

PureTech Health plc (LON:PRTC)’s stock price was up 9.8% during trading on Friday . The company traded as high as GBX 117.80 ($1.59) and last traded at GBX 116.80 ($1.57). Approximately 1,400,042 shares changed hands during mid-day trading, an increase of 89% from the average daily volume of 739,712 shares. The stock had previously closed at GBX 106.40 ($1.43).

PureTech Health Stock Performance

The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The company has a market cap of £293.65 million, a P/E ratio of 714.71 and a beta of 1.02. The stock has a fifty day moving average price of GBX 129.46 and a two-hundred day moving average price of GBX 129.76.

Insider Activity at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the firm’s stock in a transaction on Thursday, July 3rd. The stock was purchased at an average cost of GBX 1 per share, for a total transaction of £1,677.39. Insiders own 13.13% of the company’s stock.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.